Get the Stockscreener App
7.40
0.27%
-0.02
Indaptus Therapeutics Inc stock is traded at $7.40, with a volume of 2,171.
It is down -0.27% in the last 24 hours and down -32.11% over the past month.
Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.
See More
Previous Close:
$7.42
Open:
$6.9
24h Volume:
2,171
Relative Volume:
0.00
Market Cap:
$8.22M
Revenue:
-
Net Income/Loss:
$-15.42M
P/E Ratio:
-4.0217
EPS:
-1.84
Net Cash Flow:
$-13.41M
1W Performance:
-5.25%
1M Performance:
-32.11%
6M Performance:
+825.00%
1Y Performance:
+365.41%
1-Day Range:
$6.90
$7.43
1-Week Range:
$6.90
$8.1322
52-Week Range:
$0.2701
$13.40
Indaptus Therapeutics Inc Stock (INDP) Company Profile
Name
Indaptus Therapeutics Inc
Sector
Industry
Phone
(646) 427-2727
Address
3 COLUMBUS CIRCLE, NEW YORK
Compare INDP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INDP
Indaptus Therapeutics Inc
|
7.43 | 8.67M | 0 | -15.42M | -13.41M | -1.84 |
|
VRTX
Vertex Pharmaceuticals Inc
|
398.03 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
600.05 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
463.89 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
662.79 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
314.00 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Indaptus Therapeutics Inc Stock (INDP) Latest News
Indaptus Therapeutics reports Q2 EPS ($9.09) vs ($13.16) last year - MSN
Indaptus Therapeutics Inc. stock prediction for this weekTrade Exit Summary & Real-Time Stock Entry Alerts - Newser
Multi asset correlation models including Indaptus Therapeutics Inc.2025 Market Overview & Precise Swing Trade Entry Alerts - Newser
Combining price and volume data for Indaptus Therapeutics Inc.Share Buyback & Step-by-Step Trade Execution Guides - Newser
What MACD signals say about Indaptus Therapeutics Inc.Chart Signals & Fast Exit and Entry Trade Guides - Newser
What MACD and RSI say about Indaptus Therapeutics Inc.Portfolio Growth Summary & Fast Gaining Stock Reports - Newser
Signal strength of Indaptus Therapeutics Inc. stock in tech scannersDollar Strength & Stepwise Entry and Exit Trade Signals - Newser
Indaptus Therapeutics Inc. stock trendline breakdownMarket Volume Summary & Fast Exit and Entry Strategy Plans - Newser
Indaptus Therapeutics Inc. stock trend outlook and recovery pathQuarterly Growth Report & Accurate Intraday Trading Signals - Newser
Using Bollinger Bands to evaluate Indaptus Therapeutics Inc.July 2025 PostEarnings & Community Verified Trade Signals - Newser
Detecting price anomalies in Indaptus Therapeutics Inc. with AI2025 Performance Recap & AI Powered Buy/Sell Recommendations - Newser
Is Indaptus Therapeutics Inc. meeting your algorithmic filter criteriaGold Moves & Daily Entry Point Alerts - Newser
Why Indaptus Therapeutics Inc. stock attracts strong analyst attentionPortfolio Growth Summary & Long-Term Growth Portfolio Plans - Newser
Indaptus Therapeutics Inc. Tests 50 Day MA After Sharp Decline2025 Bull vs Bear & Precise Swing Trade Alerts - beatles.ru
What technical models suggest about Indaptus Therapeutics Inc.’s comebackTrade Analysis Report & Daily Oversold Bounce Ideas - Newser
How to use a screener to detect Indaptus Therapeutics Inc. breakoutsQuarterly Profit Summary & AI Enhanced Trade Execution Alerts - Newser
Using data models to predict Indaptus Therapeutics Inc. stock movement2025 Key Highlights & Low Risk Investment Opportunities - Newser
How to read the order book for Indaptus Therapeutics Inc.2025 Growth vs Value & Scalable Portfolio Growth Methods - Newser
How sentiment analysis helps forecast Indaptus Therapeutics Inc.Market Rally & Advanced Technical Signal Analysis - Newser
Indaptus Therapeutics Inc. Approaches Support With Recovery in SightTake Profit & Risk Controlled Stock Alerts - newsimpact.co.kr
Indaptus Posts Narrower Loss in Q2 - AOL.com
What to expect from Indaptus Therapeutics Inc. in the next 30 daysPortfolio Return Summary & Capital Protection Trade Alerts - Newser
Will Indaptus Therapeutics Inc. price bounce be sustainableJuly 2025 Spike Watch & Free Reliable Trade Execution Plans - Newser
How to build a dashboard for Indaptus Therapeutics Inc. stock2025 Technical Patterns & Long-Term Safe Investment Plans - Newser
Price momentum metrics for Indaptus Therapeutics Inc. explainedJuly 2025 Review & Technical Pattern Alert System - Newser
Indaptus Therapeutics Inc.’s volatility index tracking explained2025 Investor Takeaways & Consistent Growth Stock Picks - Newser
Indaptus Therapeutics Inc. Stock Support and Resistance Levels You Should KnowChart Signals & Weekly Top Stock Performers List - Newser
Maxim Group Reiterates Buy Rating for Indaptus Therapeutics - AInvest
Will Indaptus Therapeutics Inc. stock recover after recent dropTrade Exit Summary & Capital Efficient Trading Techniques - Newser
Trendline Breach Raises Concern for Indaptus Therapeutics Inc. InvestorsJuly 2025 Trade Ideas & Technical Entry and Exit Tips - 선데이타임즈
Indaptus Therapeutics Reports Q2 EPS of $9.09, CEO Highlights Clinical Milestone in Combination Trial for Decoy20 and Tislelizumab. - AInvest
Indaptus Therapeutics Raises $200M in Mixed Securities Shelf Offering - AInvest
How to escape a deep drawdown in Indaptus Therapeutics Inc.Weekly Investment Recap & Reliable Breakout Forecasts - Newser
Is Indaptus Therapeutics Inc. stock a growth or value playCEO Change & Verified Technical Signals - Newser
Indaptus Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 - MarketScreener
Indaptus Therapeutics Inc Stock (INDP) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.33%
0.64%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):